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Background: Utilisation of multidisciplinary teams is considered the best approach to care and treatment for cancer
patients. However, the multidisciplinary approach has mainly focused on inpatient care rather than routine outpatient
care. The situation in private practice care and outpatient care is gradually changing. We aimed to 1), investigate
interdisciplinary cooperations in the care of tumor patients among urologists and oncologists in the community
setting, 2), establish an estimate of the prevalence of cooperation among oncologists and organ-specific providers
in community settings in Germany and 3), characterise existing cooperations among oncologists and urologists.
Methods: We conducted simultaneously a cross-sectional survey with private practice urologists (n = 1,925) and a
qualitative study consisting of semi-structured interviews with urologists and oncologists (n = 42), primarily with
private practices, who had indicated cooperation the care of urological tumor patients.
Results: Most of the participants (66%) treated their own tumor patients. When physicians referred patients, they
did so for co- and subsequent treatments (43%). Most cooperating urologists were satisfied with the partnership
and appreciated the competency of their partners. Qualitative interviews revealed two types of collaboration in
the community setting: formal and informal. Collaborations were usually ongoing with many physicians and
depended equally on both patient preference and diagnosis.
Conclusion: Joint patient treatment requires clear delineation of roles and responsibilities and simple means of
communication. Formal frameworks should allow for incorporation of patients’ critical role in collaboration
decisions in treatment and care.
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Utilisation of multidisciplinary or multi-professional teams
in cancer care and treatment is presently considered the
best approach for cancer patient care [1-5]. Comprehen-
sive reforms were necessary to facilitate multidisciplinary
care and have been completed or are under way in the
organisational structure of health care delivery for oncol-
ogy patients around the world [4,6-9]. These revolutionary
changes in health care delivery transformed health
care systems based formerly on individual physicians’
decision-making into institutionally supported team-* Correspondence: christine.holmberg@charite.de
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article, unless otherwise stated.based approaches to treatment and care [10-12].
Multidisciplinary cancer care has improved patients’
disease management and treatment [13,14]. However,
the shift towards multidisciplinary approaches to cancer
care has largely focused on inpatient care rather than on
routine outpatient care. Similarly, research on multidiscip-
linary approaches has primarily focused on hospital
settings as well as on communication within teams, par-
ticularly in team meetings, in order to investigate the in-
fluence on treatment decision-making [10,12,15-17]. This
may be a function of how care is delivered to oncology
patients in different countries. In Germany oncological
care including systemic therapy is increasingly taking
place via outpatient care delivered by private practices ra-
ther than within hospitals. Historically, parallel structurestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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This was divided into hospital care and community-based
private practice care consisting of general practices and
specialized practices. Most patients in Germany are covered
by statutory health insurance that reimburses oncological
treatments both in hospital settings and private practice.
Such a strict divide in hospital and private practice
care is no longer feasible due to changes in treatment
and care of cancer patients. To enable and ensure inter-
disciplinary care in the community setting organ-specific
tumor-centres today bridge the gap between private-
practice and hospital-based care by incorporating both
into their structure. However, while most hospitals today
deliver cancer treatment through inter- and multiddisci-
plinary teams including psychologists, radiologists, on-
cologists, and organ-specific specialties, it is unknown
how cancer care is delivered once patients have left the
hospital [18]. In Germany oncologists and radiologists
are two separate medical sub-specialties. Historically,
care in private practice is single-physician based, thus
a shift towards team-based approaches may be more
difficult to implement in such an environment and the
necessary adaption of private practice care is only grad-
ually moving forward [19,20]. To encourage collabora-
tive efforts both within private practices and between
private practices and hospital-based care, the legal frame
of how health insurance companies reimburse private
practices for their cancer care has been restructured to
include incentives for collaborations [21-23]. Incentives
were mostly based on higher reimbursement rates for
physicians who maintain a certain level of conducting
systematic therapies in their practices. These incentives
were developed albeit little knowledge of actual private
practice care of cancer patients at the time, and such a
narrow approach has led to tensions between urologists
and oncologists [21,24-28]. How interdisciplinary collab-
oration among physicians is organized outside hospital
settings is still in question. To investigate cooperations
in the care of tumor patients in community settings we
aimed to establish an estimate of the prevalence of
cooperation among private practice oncologists and
urologists and characterize how they collaborate in
community settings in Germany. We particularly fo-
cused on the cooperation of urologists because the
shift towards multidisciplinary work for urological tumors
is fairly recent [29,30].
However, in contrast to multidisciplinary team ap-
proaches to cancer care in other countries, in Germany
current efforts to foster collaborations among private
practices caring for oncological patients focus on physi-
cians of various relevant disciplines rather than on the
inclusions of other types of health care providers. In
general, patients in Germany are free to choose which
practices deliver their care.Methods
We simultaneously conducted a cross-sectional survey
with private practice urologists to estimate the preva-
lence of cooperation and a qualitative study consisting of
semi-structured interviews with private practice urolo-
gists and oncologists who had indicated that they coop-
erated with each other in urological care to characterize
cooperations in the community setting. The study was




For the cross-sectional survey we included urologists
who worked in private practice in Germany in 2011; there
are approximately 7,000 licensed urologists [3]. Out of
these 3,500 were members of the Federal Association of
German Urologists (BDU) in 2011. More than 60% of the
BDU members (n = 1,925) operated from a private prac-
tice as of March 2011.
Data collection
We invited these 1,925 urologists via mail from the
Foundation for Men’s Health, a German nongovernmental
organisation, that included a letter introducing the study,
questionnaire and postage paid envelope. Also included
was an ID-coded postcard to be sent separately to track
respondents and ensure anonymity. In accordance with
the Dillmann method, those who had not sent back the
postcard after four weeks were sent a reminder postcard
[31]. A replacement questionnaire was sent out an add-
itional four weeks later to remaining non-responders to
increase participation rates. Those who had not responded
four weeks after the replacement questionnaire had been
sent out were considered non-responders.
The questionnaire was developed based on the aims of
the study and a literature review on factors that influ-
ence and structure cooperations among physicians. It
was tested and improved via cognitive interviewing and
then pre-tested with urologists who owned a private
practice.
The final survey consisted of 31 questions that were
divided into three sections: 1), sociodemographic infor-
mation of the physician and their private practice clien-
tele, including patient volume at the office, number of
patients with urological tumors, and extent of chemo-
therapy administered in the office, 2), urologist’s referral
behaviour, to whom patients were referred and why, 3),
prevalence and characteristics of existing cooperations
with oncologists.
Statistical analysis
For the descriptive data analysis, we used mean and
standard deviation (SD) for continuous variables and
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which factors were associated with the prevalence of an
existing cooperation we used multivariable logistic re-
gression. As independent variables we considered age of
the urologist (in years), gender (male/female), the region
in which the urologist practices (West Germany/East
Germany), and the size of the municipality where the
urologist’s practice is located (divided into three categories
by size: small towns with <20,000 inhabitants, mid-size
towns with 20,000-100,000 inhabitants, or larger towns
with >100,000 inhabitants), and whether they were sole
operators of their practice or worked in a joint practice
and whether they were members of an interdisciplinary
tumor centre (yes/no). Correlation analyses showed that
no colinearity was prevalent between the independent
variables, an assumption for the logistic regression.
All statistical analyses were performed using Stata IC




For the qualitative study, we selected tandems of cooper-
ating urologists and oncologists. To identify such tan-
dems, 49 members of the Scientific Institute of Private
Practice Hematologists and Oncologists were contacted
and screened for participation. In addition, the Founda-
tion for Men’s Health contacted urologists to screen
them for participation; these physicians were asked to
indicate with whom they collaborated in the care of pa-
tients with urological tumors. If an oncologist and an
urologist indicated each other they were invited to par-
ticipate in the interview study. In addition, to reflect the
practice of urological care in Germany in which much of
the care takes place between generalising urologists and
urologists specialised in oncology care, a select sample
of urologists who specialised in oncology care and per-
formed intravenous chemotherapies were asked to par-
ticipate in the interview study. To reflect cooperations
between hospitals and private practice urologists we
invited two chiefs of medicine from oncology hospital
departments to join the interview study.
Data collection
Twenty-one identified pairs of collaborating urologists
and oncologists were interviewed individually. The inter-
view guideline was developed based on the study aims
and the literature review. It included questions regarding
the practice, cooperation with the other physician and
operational framework for cooperation including related
conditions, barriers and enabling factors of the particular
cooperation and of cooperations in general. To ensure
anonymity of participants, interviewees were assigned
identification numbers with which transcribed interviewswere pseudonymised. All interviewees signed informed
consent forms.
Analysis
Interview transcripts were entered into MAXQDA 10
and analyzed thematically with regards to tandem cooper-
ation specifically between the two physicians, any other
collaborations they discussed, and barriers and/or enab-
ling factors for collaborations with other physicians. Codes
were developed inductively from the interview material.
After an initial round of coding, categories were developed
and codes were grouped within the categories. Two
authors (CH and DC) coded materials and resolved
differential coding. In addition to thematic coding, the
interviews of the tandems were compared to each
other; a case report developed for every tandem was
discussed by the two coders. All steps of analysis were
regularly presented and discussed within a qualitative




The overall questionnaire response rate was 40% (n = 731).
Of the responding urologists, 92% were male. The average
age of participants was 51.8 years (SD: 6.8). Most of the
physicians worked as sole operators (48%) and 44%
worked in a joint practice. On average, they had oper-
ated their practice for 14.4 years (SD: 7.1). Most of the
participants practiced in towns with 20,000-100,000
inhabitants (38%) or in towns with more than 100,000
inhabitants (38%) whereas 22% practiced in more rural
areas (i.e., in towns with less than 20,000 inhabitants).
63% of responders were members of an interdisciplinary
tumor centre. During the fourth quarter of 2011, 76% of
participants had diagnosed at least one urological tumor;
50% of participants had administered between one and
ten chemotherapies while the remaining 50% of the
sample had not performed any chemotherapy.
Referrals
Most participants (66%, n = 482) treated their tumor pa-
tients themselves. Of the remaining responders (n = 249),
15% referred their patients to a specialised urologist, 9% to
an oncologist, and 10% to a clinic. The reasons for transfer-
ring patients were treatment-related (43%), to seek a second
opinion (15%) or for a consultative examination (3%).
Collaborations
Reasons in favour of or opposition to cooperations with
oncologists or with oncology-qualified urologists are
displayed in Table 1.
A total of 437 physicians (59.8%) stated that they col-
laborated with oncologists or other urologists (Table 2).
Table 1 Urologists’ reasons for or against cooperation with
oncologists or urologists specialised in oncology carea
Reasons All participants
(n = 731) n (%)
In favour of cooperation
To offer additional treatments 242 (31.1)
To improve patient care 264 (36.1)
It is mandated by the health insurance company 77 (10.5)
Opposed to cooperation
I can offer all treatments needed by patients with
urological tumors
291 (39.8)
I have had negative experiences with collaborations 14 (1.9)
I am worried I would lose patients 2 (0.3)
aNumbers do not sum up to 100% because multiple answers were allowed.
Table 2 Description of existing cooperation





Most frequent cooperating partner
Oncologist 155 (35.5)
Urologist specialised in oncology 260 (59.5)
No information 22 (5.0)
Acquaintance with cooperation partner
I am well acquainted with my cooperation
partner
343 (78.5)
I am slightly acquainted with my cooperation
partner
62 (14.2)
I don’t know my cooperation partner in person 8 (1.8)
No information 24 (5.5)
Distance to cooperating partner
In same building 29 (6.6)
In walking distance (≤3 km) 98 (22.4)
Near distance (3–10 km) 153 (35.0)
Moderate distance (11–30 km) 108 (24.7)
Far distance (>30 km) 25 (5.7)
No information 24 (5.5)
Who determines the treatment?
I determine the treatment 64 (14.6)
My colleague determines the treatment 16 (3.7)
My colleague and I determine together 338 (77.3)
No information 19 (4.3)
Who administers the therapy?
I supervise/administer the therapy 52 (11.9)
My cooperation partner supervises/administers
the therapy
99 (22.7)
My cooperation partner and I jointly
supervise the therapy
264 (60.4)
No information 22 (5.0)
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gether they decided on treatment and supervised the pa-
tient. Follow-up care remained with the urologist in the
majority of cases (Table 2). Most of the cooperating
urologists were satisfied (40%) or very satisfied (45%)
with the partnership. They especially appreciated the
competency of their partners (81%). The urologists ap-
preciated the non-bureaucratic exchange with their col-
leagues (72%) and the clear distribution of roles and
responsibilities for care (35%).
Logistic regression analyses clarified factors associated
with likeliness of establishing cooperation (Table 3).
Urologists in West Germany were less likely to cooper-
ate (OR = 0.51, p = 0.003) as compared to urologists in
East Germany. Urologists working as sole operators of
their practice were more likely to cooperate (OR = 1.54;
p = 0.016). Membership to a tumor centre increased the
likelihood to cooperate (OR = 1.85; p < 0.001). We did
not find a significant association between the prevalence
of an existing cooperation and the urologists’ age and
gender, the size of the town, or the number of onco-
logical treatments in a practice.Who is responsible for follow-up care?
I am responsible for follow-up care 270 (61.8)
My cooperation partner is responsible for
follow-up care
11 (2.5)
My cooperation partner and I are both
responsible
134 (30.7)
No information 22 (5.0)Qualitative study component
Of 49 oncologists, 25 agreed to participate in the quali-
tative study section. Of those a sub-sample of 12 could
be matched with a cooperating urologist. Of 20 addition-
ally contacted urologists, 15 agreed to participate and a
matching team of 6 urologists and oncologists could be
established. This led to 18 urologist-oncologist tandems
for the study. Of 10 urologists who specialise in intra-
venous chemotherapy, 3 tandems could be identified.
Thus an overall sample of 21 matched sets of urologists
and oncologists participated in the study.
The tandem partners were not necessarily in close nor
exclusive collaboration. All interviewed physicians were
collaborating with many physicians. With whom theycollaborated at any time depended on the disease, the
type of treatment, and patient preference.Collaboration: formal and informal
Physicians described two types of collaborations. Informal
collaborations included patient referral for additional
Table 3 Factors associated with the likelihood of establishing a cooperationa
Variables Characteristic OR (95% CI) P value
Age (years) 1.02 (1.00; 1,05) 0.056
Gender Male 0.81 (0.42; 1.59) 0.546
Female [Reference]
Region West Germany 0.51 (0.33; 0.79) 0.003
East Germany [Reference]
Sole operator of private practice Yes 1.54 (1.08; 2.19) 0.016
No [Reference]
Size of the town >100,000 inhabitants 1.50 (0.96; 2.35) 0.074
20,000-100,000 inhabitants 1.11 (0.73; 1.69) 0.620
<20,000 inhabitants [Reference]
Member of a tumor centre Yes 1.85 (1.32; 2.60) 0.000
No [Reference]
Number of treated patients 1001-1500 patients 0.99 (0.65; 1.50) 0.962
> 1500 patients 0.80 (0.50; 1.29) 0.367
≤1000 patients [Reference]
aNumber of included participants: 626.
CI = confidence interval, OR = odds ratio.
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cancer care and open to discussing patient treatment op-
tions. Formal collaborations were usually characterised by
contracts between one or several private practices and
hospitals, with the exception of one case which only in-
volved private practices.
Informal collaborations
For informal collaborations the urologist functioned as
gatekeeper for the patient, choosing when and with
whom to collaborate and when to offer a referral to the
patient. Urologists decided whether or not to include a
second physician based on: 1), diagnosis the patient was
given, 2), stage of the tumor, and 3), type of therapy
prescribed.
This involved flexible cooperation partners; physicians
to which a patient was referred varied case by case.
Choosing whom to collaborate with depended on prefer-
ences of both physician and patient.
“This is also decided by the patient. It depends on
accessibility and the patient’s place of residence. (…)
The patient is offered different options when we discuss
outpatient administration of chemotherapy. The patient
then participates in the decision.” (Urologist 12B).
“Proximity [of treatment] is always good but it is not
absolutely necessary. If this isn’t the case, it’s also okay.
But you need to offer the patient the options: ‘Do you
want to go someplace near where you live if it is
feasible?’ Everyone has to decide that on their own.”
(Urologist 9B).Urologists collaborated most often with oncologists
for systemic therapies, particularly intravenous chemo-
therapy which required several employees to handle the
delivery of treatment. Physical constraints on personnel
led urologists to refer patients to oncologists for com-
plex systemic treatments.
“So for example the manpower I have. If I have a
young man with testicular cancer, tumor Stage 2C,
bulky disease, who needs combination chemotherapy,
four cycles. You really need to be accurate there. You
have to make sure the timing of the cycles is okay. You
cannot allow times when this is not possible [to
administer the chemotherapy]. For me in my private
practice to do that, there are clear limitations. I once
had three testicular cancers at one time; you need to
plan for all of them. You can’t just say, ‘sorry, I don’t
have time, we will only do three cycles’. Or, ‘I am on
my vacation; we will just do the cycle two weeks later.’
You can’t do that. And that is why you really need to
be part of a network.” (Urologist 8B).
Formal collaborations
At the time of the interviews formal collaborations were
only in a developmental stage, mainly consisting of par-
ticipation in tumor boards organised by hospitals and
private practices from different areas. In some cases the
oncologist had formally agreed to administer therapies
for the tandem urologist’s clientele. These arrangements
were in part a response to recent changes in the reim-
bursement scheme for private practice physicians that
treat cancer patients.
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collaborations, varying views about how tumor boards
should be organised, including how and which patients
should be discussed, was a point of discussion in the in-
terviews. Physicians discussed the issue of time and case
selection for the tumor boards. The presentation of all
tumor patients required a significant time commitment
of physicians, so that this was not necessarily seen as the
best approach. However, some oncologists feared the
selection of cases presented at the tumor board might be
presented too late to the other specialists.
“There are some clearly defined situations when the
tumor stage tells you what to do. Those should not be
discussed at length in tumor boards.” (Oncologist 6A.)
“It does not make sense to discuss standard cases. (…)
The cases in which you can really discuss different
alternatives, additional diagnostic tests- those are
really interesting. These are the rare cases. That makes
tumor boards interesting.” (Urologist 11B).
“Maybe it would be good if tumor boards would be
held more often. That would be a possibility. However,
we already have plenty of them, and it may just be too
much. (…) And sometimes it would be good if we were
asked before a treatment regimen is decided, before
they realise the treatment is not working as intended.
And only then is one asked to consult on the case. It
would be nice if one were asked before and decided on
a treatment together. So if we would discuss patients
before they start treatment. But reality often looks
different than that.” (Oncologist 15A).
“When patients have been treated for years by the
urologist even though it was clear that the course of
the disease will be deadly and only when they
reach the final stage then they come to us without
being able to build up a relationship in this final
phase. (…). So I would appreciate that if it becomes
obvious that hormonal therapy is not working
patients are transferred quickly so that we can
build a relationship and organise treatment.”
(Oncologist 11A).
Characteristics of collaborations that were perceived
favourably
Physicians emphasised that the communicative methods
and timing for exchanging information about the patient
was the single most important aspect to classify a part-
nership as a good one. Success was defined by a quick
and simple way of exchanging information about pa-
tients and treatment options. Phoning provided a perfect
means for these interactions.“What I like is that when I send a patient to him, he
then talks on the phone with me, tells me what he
found, discusses it with me and sends me the results.
(…) The cooperation is good. And the treatment of the
patients is really good.” (Urologist 14B).
“So I make the indication. I discuss it with the patient.
I offer the patient to make an appointment with [the
collaborating physician]. Sometimes they need some
time to think about it. Others say ‘yes, please.‘ So
depending on what the patient wants, I call them and
if it is urgent I ask to be transferred to the oncologist
and discuss the therapy plan immediately with the
oncologist.” (Urologist 2B).
The importance of communication for successful collab-
oration highlighted joint treatment decisions. Discussions
about treatment options were a way for collaborating phy-
sicians to recognise another’s competency in their respect-
ive field. Such an acknowledgement improved the ways
physicians evaluated their collaborations.
“I take the CT results to discuss with the oncologist.
Sometimes we do it during the tumor board and
sometimes before. And then I ask him if he would
recommend a change in treatment based on the
results. We then go back and forth with our opinions
and form a decision. The cooperation works because it
is not as if he is taking away patients but that we take
care of them together and decide jointly who will
administer the treatment.” (Urologist 21B).
Discussion
In Germany, the establishment of new forms of reim-
bursement systems was underway to support interdiscip-
linary cooperation in community settings [21-23]. Their
intention was to facilitate and encourage the development
of collaborations among physicians. These developments
however, were accompanied by tensions between urolo-
gists and oncologists [24-26,28,32]. While the qualitative
interviews showed the development of formal collabora-
tions, the quantitative and qualitative data combined
showed it would be misleading to suggest that private
practice physicians have not collaborated in the care of
their tumor patients previously. Indeed, most surveyed
physicians thought that collaborations among physicians
are important and many worked together with another
physician to deliver optimal treatment to their patients.
The most important aspects for a successful and satisfac-
tory cooperation were simple communication structures
and knowing one’s partner. The possibility to discuss pa-
tients and secure appointments in a timely fashion were
factors that facilitated collaborations. The difference in
collaboration frequency between urologists residing in
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inherent to the different health care systems in the former
German Democratic Republic (GDR, East) and the former
Federal Republic of Germany (FRG, West). Health policy
in the GDR was focused on establishing clinics in which a
variety of medical specialties worked together (polyclinics
and ambulatories), whereas the health care system in the
FRG strongly favored single-physician practices, and a
strict separation between hospital care and out-patient
care predominantly delivered by single-physician private
practices. These distinctive infrastructures still play a role
in health care delivery in the two geographical regions.
Research that has focused on the collaborations among
physicians thus far has focused on general practitioners
and their interactions with other specialised and organ-
specific physicians. These have identified communica-
tion of information between office-based physicians as a
barrier to collaborations [33]. In another study commu-
nication and accessibility of a physician was identified as
influencing physicians’ preferences to refer patients to
other physicians [34]. Time and the perception of the
competency of other physicians and their ability to serve
the patient well have been found as barriers to refer pa-
tients from general practice to other medical disciplines
[35]. In our study, satisfactory partnerships were associ-
ated with the respect that cooperating physicians felt for
their partners as well as the clear distribution of roles and
responsibilities. In contrast to Belgium, where roles and
responsibilities were clearly defined in laws that have
restructured the oncological field, such clarity of role def-
inition has not been a major focus in restructuring the
German oncological field in community settings [36,37].
Physicians in this study considered joint treatment
decision-making as collaboration. This is the main char-
acteristic of tumor board conferences pertaining to formal
collaboration structures [16,38]. However the study re-
vealed such communication and joint treatment decisions
also took place in more informal settings. Physicians in-
volved colleagues in the care of their tumor patients when
they considered additional treatments necessary. While
there was no standardised way of how physicians decided
when this was necessary, this was also true for the more
formal collaborations.
The design of the qualitative study assumed a form of
collaboration among physicians that did not exist. In-
deed, urologists and oncologists worked in a myriad of
relationships with many other physicians. There was no
single type of collaboration rather it depended on the
patient’s wish as much as on the physician’s assessment.
Patients have not been the focus of the study however
the patient plays a crucial role in decision-making about
with whom care is jointly delivered (or not). Ultimately,
it was the patient’s choice to accept a recommended
physician or not. As the push to more interdisciplinaryteam approaches moves forward, it is paramount to
study patient perspectives on care delivery.
Besides neglecting the patients’ point of view, another
limitation was the response rate for the survey (40%).
Responders were likely positively attuned to collabor-
ation among physicians. This could explain the positive
attitude regarding collaborations in general and the high
prevalence of existing collaborations among the respon-
dents. This may also be true for the responders of the
qualitative study section. Participants of the interview
study were willing to spend several hours in an interview
that discussed physician collaboration. Presumably, they
had a personal interest in the topic. They also had to be
in an existing collaboration with an urologist/oncologist
who was also willing to participate in the interview
study. This implies both that they want to cooperate and
a greater likelihood that they were engaged in a good
collaboration. We therefore do not know what barriers
would be described by physicians who assess a less posi-
tive view regarding collaborations among physicians. Fi-
nally, we did not include physicians working in hospital
settings since we aimed to learn particularly about pri-
vate practice collaborations. However, it would be inter-
esting to compare the views of urologists who work in
hospital settings and have been collaborating for some
time in cancer centers with private practice colleagues.
To develop models of collaborations such views may
prove important to identify best practices and identify
other barriers that hinder good collaboration.
Conclusion
In the care of their urological tumor patients physicians
collaborated in many ways with other physicians to en-
hance treatment options for patients. Physicians decided
when to introduce a patient both formally or informally
to other medical professionals. If collaborations among
physicians shall be embedded within a more standardised
framework it may be important to formulate more clearly
which patients should be treated interdisciplinarily, estab-
lish simple and direct communication strategies among
cooperation partners, and to ensure joint treatment deci-
sions by in part respecting each other’s competencies.
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